Advanced search
Publication Cover
Acta Oncologica Volume 45, 2006 - Issue 4
Journal homepage
1,748
Views
9
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

Tamar Safra Department of Medical Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, IsraelCorrespondence[email protected]
,
Ilan Ron Department of Medical Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
,
Mona Boaz Epidemiology and Research Unit, Wolfson Medical Center, Holon, Israel
,
Joseph Brenner Division of Medical Oncology Wolfson Medical Center, Holon, Israel
,
Dan Grisaru Department of Obstetrics and Gynecology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
,
Moshe Inbar Department of Medical Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
,
Henry Hayat Division of Medical Oncology Wolfson Medical Center, Holon, Israel
,
Joseph Menczer Division of Gynecologic Oncology, Wolfson Medical Center, Holon, Israel
,
Abraham Golan Department of Obstetrics and Gynecology Wolfson Medical Center, Holon, Israel
&
Tally Levy Division of Gynecologic Oncology, Wolfson Medical Center, Holon, Israel
 show all
Pages 463-468 | Received 09 Aug 2005, Published online: 08 Jul 2009

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Koji Matsuo, Yvonne G Lin, Lynda D Roman & Anil K Sood. (2010) Overcoming platinum resistance in ovarian carcinoma. Expert Opinion on Investigational Drugs 19:11, pages 1339-1354.
Read now

Articles from other publishers (8)

A. A. Rumyantsev, A. S. TyulyandinaE. R. Israelyan, I. A. Pokataev, M. Yu. Fedyanin, E. V. Glazkova, Yu. S. SergeevS. A. Tjulandin. (2022) Efficacy of non‑platinum chemotherapy in platinum‑resistant ovarian cancer: a meta‑analysis. Malignant tumours 12:1, pages 21-35.
Crossref
Felicitas Kuehne, Ursula Rochau, Noman Paracha, Jennifer M. Yeh, Eduardo Sabate & Uwe Siebert. (2021) Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. Medical Decision Making 42:2, pages 194-207.
Crossref
L.R. Duska, G.R. Petroni, N. Varhegyi, J. Brown, D. Jelovac, K.N. Moore, W.P. McGuire, C. Darus, L.M. Barroilhet & A.A. Secord. (2020) A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecologic Oncology 157:3, pages 585-592.
Crossref
Ofer Lavie, David Edelman, Tally Levy, Ami Fishman, Ayala Hubert, Yakir Segev, Eli Raveh, Michal Gilon & Avraham Hochberg. (2017) A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer. Archives of Gynecology and Obstetrics 295:3, pages 751-761.
Crossref
Yuji Takei, Yoshifumi Takahashi, Shizuo Machida, Akiyo Taneichi, Suzuyo Takahashi, Tomomi Nagashima, Hiroyuki Morisawa, Yasushi Saga, Shigeki Matsubara & Hiroyuki Fujiwara. (2017) Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens. Journal of Obstetrics and Gynaecology Research 43:2, pages 358-364.
Crossref
Gabriella Ferrandina, Giacomo Corrado, Floriana Mascilini, Paola Malaguti, Riccardo Samaritani, Mariagrazia Distefano, Valeria Masciullo, Alessia Di Legge, Antonella Savarese & Giovanni Scambia. (2014) Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study. BMC Cancer 14:1.
Crossref
José María del Campo, Cristiana Sessa, Carolyn N. Krasner, Jan B. Vermorken, Nicoletta Colombo, Stan Kaye, Martin Gore, Patrik Zintl, Javier Gómez, Trilok Parekh, Youn Choi Park & Scott McMeekin. (2013) Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Medical Oncology 30:1.
Crossref
Shin Komiyama, Masaru Nakamura, Isao Murakami, Yoshiko Kuwabara, Takashi Kurahashi, Kyoko Tanaka & Mikio Mikami. (2007) A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. Archives of Gynecology and Obstetrics 278:6, pages 565-568.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.